Perspectives on long-acting growth hormone therapy in children and adults
Growth hormone therapy with daily injections of recombinant human growth hormone has been available since 1985, and is shown to be safe and effective treatment for short stature in children and for adult growth hormone deficiency. In an effort to produce
Rayhan A. Lal, Andrew R. Hoffman
doaj +1 more source
Background The treatment with recombinant human growth hormone in patients affected by Mucopolysaccharidoses (MPS) is considered whenever a concurrent diagnosis of growth hormone deficiency is demonstrated. The short- and long-term effects of recombinant
A. Cattoni +5 more
doaj +1 more source
Enhancement of The Stability of Human Growth Hormone by Using Tris(hydroxymethyl)aminomethane: Molecular Docking and Experimental Analysis [PDF]
Objective: It is so difficult to formulate human growth hormone (hGH) in a solution with high stability and new drug delivery system (NDDs) due to physiochemical instability. The purpose of this study was to investigate the possibility of using Tris as
Siyavash Mirzaei +6 more
doaj +1 more source
Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data [PDF]
In 2006, the European Medicines Agency (EMA) approved Omnitrope(®) as a biosimilar recombinant human growth hormone (rhGH), on the basis of comparable quality, safety, and efficacy to the reference medicine (Genotropin(®), Pfizer).
Zabransky, Markus +11 more
core +2 more sources
Monocarboxylate transporter 8 modulates the viability and invasive capacity of human placental cells and fetoplacental growth in mice [PDF]
Monocarboxylate transporter 8 (MCT8) is a well-established thyroid hormone (TH) transporter. In humans, MCT8 mutations result in changes in circulating TH concentrations and X-linked severe global neurodevelopmental delay.
Laurence S Loubière +83 more
core +1 more source
Short Stature in children: Review Article
Background: Humans' final adult height is influenced by a variety of factors. A common paediatric endocrine issue, short stature has a variety of reasons, but normal variations account for the majority of cases.
Ahmed El-Abd Ahmed +3 more
doaj +1 more source
Ten years of biosimilar recombinant human growth hormone in Europe [PDF]
Paul Saenger Division of Pediatric Endocrinology, Department of Pediatrics, Winthrop University Hospital, Mineola, NY, USA Abstract: Recombinant human growth hormone (rhGH) has been in clinical use for more than 30 years.
Saenger P, Paul Saenger
core +2 more sources
Jintrolong® is a long-acting PEGylated recombinant human growth hormone (PEG-rhGH) developed for weekly injection in patients with pediatric growth hormone deficiency (PGHD). Although PEG modification of therapeutic proteins is generally considered safe,
Wei Wu +15 more
doaj +1 more source
Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism [PDF]
Defects of either anosmin-1 or fibroblast growth factor receptor 1 (FGFR1) are known to underlie hereditary Kallmann's syndrome (KS), a human disorder of olfactory and gonadotropin-releasing hormone (GnRH) neuronal ontogeny.
Guimond, S +17 more
core +1 more source
Introduction and purpose Recombinant human growth hormone (rhGH) therapy has been the standard treatment for paediatric short stature for many years, and a therapeutic option for the replacement therapy of growth hormone deficiency in the post ...
Agata Kotkowiak +9 more
doaj +1 more source

